End of Year Message from Kristin Bonham to Our Customers

Dear dsm-firmenich ANH Customers,

It’s hard to believe we are wrapping up 2022 already. As I reflect on this past year, I’m grateful for the relationships we’ve continued to build with you and your colleagues, and I’m appreciative of the trust you’ve put into dsm-firmenich and our representatives. We value your partnership and business and look forward to continuing to deliver best in class products to you in the years ahead.

Looking to 2023, our team is busy preparing for the opportunities and challenges to come. The cumulative effects of the Covid-19 pandemic, geopolitical tensions, and rising energy and raw material costs are putting increasing pressure on supply chains across the world, bringing up challenges in availability and affordability of products and ingredients. We have all felt and are still feeling the strain in our operations on a daily basis. With economic and political uncertainty on the rise around the world, companies involved in delivering critical food items must take steps to ensure all-important security of supply for their customers and society at large.

At dsm-firmenich, we look beyond cost-saving, and resist the industry trend toward offshoring and concentrating production in specific parts of the world. Over the years we have maintained our assets in the heart of Europe and have upgraded these to stay competitive and lead in sustainable production. We build on more than 100 years of innovation and production history, the power of which is illustrated by our launch of the world’s first bio-based vitamin A made in Sisseln (Switzerland). A clear example of how investment in European production can create robust and environmentally responsible sources of vital products. As an integral part of the global food system, we are committed to maintain our strong “Made In Europe” manufacturing base.

Within the US, you may have recently seen an announcement on the latest innovation we’re bringing you, FUMzyme®, fumonisin esterase, for use in poultry and swine. FUMzyme is the first-ever FDA-approved purified enzyme to specifically and irreversibly degrade fumonisins into non-toxic metabolites. We’re excited about this and other new offerings and look forward to bringing you even more innovation in 2023 and beyond.

As we prepare for next year, we are committed to do whatever we can to secure long-term competitive supply for your business. We hope we can build on our strong relationship to maintain current and future resilience of the food supply chain and thereby together play a leading role in food security for all.

Kind Regards,

Kristin Bonham

Vice President, dsm-firmenich Animal Nutrition & Health, North America